Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Prometic reports its 2019 first quarter financial results

Canada NewsWire May 8, 2019

Prometic strengthens its leadership with a new management structure and the appointment of three new directors

Canada NewsWire May 8, 2019

Prometic Completes Refinancing Transactions Including C$75 Million (approximately US$56 Million) in Gross Proceeds from New Equity Financing

Canada NewsWire April 23, 2019

Prometic reports fourth quarter and 2018 year-end financial results

Canada NewsWire April 1, 2019

Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast

Canada NewsWire March 26, 2019

Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities

Canada NewsWire March 25, 2019

Prometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities

Canada NewsWire February 25, 2019

Prometic retains investment bank for strategic transactions

PR Newswire February 14, 2019

Prof. Simon Best Appointed Interim CEO of Prometic Life Sciences

Canada NewsWire December 19, 2018

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

Canada NewsWire December 5, 2018

Prometic Provides Corporate Update

Canada NewsWire November 28, 2018

Prometic Reports Third Quarter 2018 Financial Results and Highlights

Canada NewsWire November 14, 2018

Prometic Closes its Extension of Debt Maturities to 2024

PR Newswire November 14, 2018

Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast

PR Newswire November 12, 2018

Prometic Announces Extension of Debt Maturities to 2024

PR Newswire October 29, 2018

Prometic announces second annual Plasminogen Deficiency Awareness Week

PR Newswire October 25, 2018

Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA

PR Newswire October 16, 2018

Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH)

Canada NewsWire September 5, 2018

Prometic Reports Second Quarter 2018 Financial Results and Highlights

Canada NewsWire August 14, 2018

Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics

Canada NewsWire August 10, 2018